Drug intelligence / Profile preview

elevATP

Development stage: Unknown
Lead developer: VDF FutureCeuticals
Administration: Oral

Overview

elevATP is a proprietary, clinically researched combination of ancient peat (trace minerals) and apple extract (polyphenols) developed by FutureCeuticals. It is designed to increase endogenous levels of adenosine triphosphate (ATP), the primary energy currency of cells, without the need for exogenous ATP supplementation. The supplement is primarily marketed as a sports nutrition ingredient to improve athletic performance, power output, and body composition in resistance-trained individuals. Clinical studies, including NCT02819219, have evaluated its effects on muscle hypertrophy and performance metrics during periodized resistance training, demonstrating its ability to increase whole-blood ATP levels.

Brand names: elevATP
Other names: Ancient peat and apple extract

Beyond the preview

Go deeper on elevATP.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on elevATP.

Explore the full profile